Literature DB >> 26348103

MR Enterography for the Evaluation of Small-Bowel Inflammation in Crohn Disease by Using Diffusion-weighted Imaging without Intravenous Contrast Material: A Prospective Noninferiority Study.

Nieun Seo1, Seong Ho Park1, Kyung-Jo Kim1, Bo-Kyeong Kang1, Yedaun Lee1, Suk-Kyun Yang1, Byong Duk Ye1, Sang Hyoung Park1, So Yeon Kim1, Seunghee Baek1, Kyunghwa Han1, Hyun Kwon Ha1.   

Abstract

PURPOSE: To determine whether magnetic resonance (MR) enterography performed with diffusion-weighted imaging (DWI) without intravenous contrast material is noninferior to contrast material-enhanced (CE) MR enterography for the evaluation of small-bowel inflammation in Crohn disease.
MATERIALS AND METHODS: Institutional review board approval and informed consent were obtained for this prospective noninferiority study. Fifty consecutive adults suspected of having Crohn disease underwent clinical assessment, MR enterography, and ileocolonoscopy within 1 week. MR enterography included conventional imaging and DWI (b = 900 sec/mm(2)). In 44 patients with Crohn disease, 171 small-bowel segments that were generally well distended and showed a wide range of findings, from normalcy to severe inflammation (34 men, 10 women; mean age ± standard deviation, 26.9 years ± 6.1), were selected for analysis. Image sets consisting of (a) T2-weighted sequences with DWI and (b) T2-weighted sequences with CE T1-weighted sequences were reviewed by using a crossover design with blinding and randomization. Statistical analyses included noninferiority testing regarding proportional agreement between DWI and CE MR enterography for the identification of bowel inflammation with a noninferiority margin of 80%, correlation between DWI and CE MR enterography scores of bowel inflammation severity, and comparison of accuracy between DWI and CE MR enterography for the diagnosis of terminal ileal inflammation by using endoscopic findings as the reference standard.
RESULTS: The agreement between DWI and CE MR enterography for the identification of bowel inflammation was 91.8% (157 of 171 segments; one-sided 95% confidence interval: ≥88.4%). The correlation coefficient between DWI and CE MR enterography scores was 0.937 (P < .001). DWI and CE MR enterography did not differ significantly regarding the sensitivity and specificity for the diagnosis of terminal ileal inflammation (P > .999). DWI and CE MR enterography concurred in the diagnosis of penetrating complications in five of eight segments.
CONCLUSION: DWI MR enterography was noninferior to CE MR enterography for the evaluation of inflammation in Crohn disease in generally well-distended small bowel, except for the diagnosis of penetration.

Entities:  

Mesh:

Year:  2015        PMID: 26348103     DOI: 10.1148/radiol.2015150809

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  39 in total

1.  Potential of diffusion-weighted imaging in magnetic resonance enterography to identify neoplasms in the ileocecal region: Use of ultra-high b-value diffusion-weighted imaging.

Authors:  Hao Yu; Cui Feng; Zi Wang; Jianjun Li; Yanchun Wang; Xuemei Hu; Zhen Li; Yaqi Shen; Daoyu Hu
Journal:  Oncol Lett       Date:  2019-06-05       Impact factor: 2.967

2.  Comparison of 3D magnetic resonance imaging and digital subtraction angiography for intracranial artery stenosis.

Authors:  Ji Eun Park; Seung Chai Jung; Sang Hun Lee; Ji Young Jeon; Ji Ye Lee; Ho Sung Kim; Choong-Gon Choi; Sang Joon Kim; Deok Hee Lee; Seon-Ok Kim; Sun U Kwon; Dong-Wha Kang; Jong S Kim
Journal:  Eur Radiol       Date:  2017-05-12       Impact factor: 5.315

3.  Diffusion-weighted MR enterography for evaluating Crohn's disease: Effect of anti-peristaltic agent on the diagnosis of bowel inflammation.

Authors:  So Hyun Park; Jimi Huh; Seong Ho Park; Seung Soo Lee; Ah Young Kim; Suk-Kyun Yang
Journal:  Eur Radiol       Date:  2016-10-05       Impact factor: 5.315

4.  Preoperative evaluation of small bowel complications in Crohn's disease: comparison of diffusion-weighted and contrast-enhanced MR imaging.

Authors:  M Barat; C Hoeffel; M Bouquot; A S Jannot; R Dautry; M Boudiaf; K Pautrat; R Kaci; M Camus; C Eveno; M Pocard; P Soyer; A Dohan
Journal:  Eur Radiol       Date:  2018-10-09       Impact factor: 5.315

5.  Ability of DWI to characterize bowel fibrosis depends on the degree of bowel inflammation.

Authors:  Xue-Hua Li; Ren Mao; Si-Yun Huang; Zhuang-Nian Fang; Bao-Lan Lu; Jin-Jiang Lin; Shan-Shan Xiong; Min-Hu Chen; Zi-Ping Li; Can-Hui Sun; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2019-01-11       Impact factor: 5.315

6.  Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and decreased risk of surgery in Crohn's disease.

Authors:  Anthony Buisson; Constance Hordonneau; Felix Goutorbe; Christophe Allimant; Marion Goutte; Maud Reymond; Bruno Pereira; Gilles Bommelaer
Journal:  J Gastroenterol       Date:  2018-08-30       Impact factor: 7.527

7.  Diagnostic accuracy of non-contrast magnetic resonance enterography in detecting active bowel inflammation in pediatric patients with diagnosed or suspected inflammatory bowel disease to determine necessity of gadolinium-based contrast agents.

Authors:  Stacy J Kim; Thomas L Ratchford; Paula M Buchanan; Dhiren R Patel; Ting Y Tao; Jeffrey H Teckman; Jeffrey J Brown; Shannon G Farmakis
Journal:  Pediatr Radiol       Date:  2019-03-21

Review 8.  Small Bowel Imaging: an Update.

Authors:  Jordi Rimola; Julián Panés
Journal:  Curr Gastroenterol Rep       Date:  2016-07

9.  Update on Magnetic Resonance Imaging and Ultrasound Evaluation of Crohn's Disease.

Authors:  Parakkal Deepak; Amy B Kolbe; Jeff L Fidler; Joel G Fletcher; John M Knudsen; David H Bruining
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-04

10.  Comparison of three magnetic resonance enterography indices for grading activity in Crohn's disease.

Authors:  Jordi Rimola; Almudena Alvarez-Cofiño; Tamara Pérez-Jeldres; Carmen Ayuso; Ignacio Alfaro; Sonia Rodríguez; Elena Ricart; Ingrid Ordás; Julián Panés
Journal:  J Gastroenterol       Date:  2016-09-06       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.